Healthcare Services

Global Patient Derived Xenograft (PDX) Models Market Forecast 2026–2035: Long-Term Growth Insights

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the patient derived xenograft (pdx) models market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Patient Derived Xenograft (PDX) Models Market from 2026 to 2030?

The patient derived xenograft (pdx) models market has seen rapid expansion in recent years. It is forecast to grow from $0.47 billion in 2025 to $0.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.8%. This historical growth can be attributed to factors such as the limited predictive capability of traditional cell line models, increasing cancer research initiatives, the reliance on animal models for drug testing, a growing demand for translational oncology studies, and the expansion of academic and pharmaceutical research collaborations.

The patient derived xenograft (pdx) models market is set for rapid expansion in the coming years, with projections indicating a rise to $0.92 billion by 2030, at a compound annual growth rate (CAGR) of 14.0%. This anticipated growth is driven by factors such as the increasing adoption of pdx models for precision medicine, greater investment in humanized mouse and rat models, the expansion of co-clinical trial programs, the broadening services of contract research organizations offering pdx solutions, and the growing application of pdx models for evaluating immunotherapy and targeted therapies. Significant trends for this period include the rising use of pdx models for preclinical drug development, a heightened focus on personalized cancer research utilizing these models, the increasing integration of digital platforms for tumor data management, greater utilization of humanized and genetically modified models, and the expanding scope of co-clinical trials that leverage pdx models.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp

What Drivers Are Affecting Demand In The Patient Derived Xenograft (PDX) Models Market?

The patient-derived xenograft (PDX) models market is anticipated to expand, driven by the escalating demand for personalized medicine. This approach involves tailoring medical treatment to each patient’s unique characteristics, taking into account factors such as genetics, environment, and lifestyle. The rising demand for personalized medicine is due to advancements in genomic research, which enable customized treatments based on individual genetic profiles, leading to more effective and targeted healthcare outcomes. Patient-derived xenograft (PDX) models facilitate personalized medicine by allowing the testing of individual patient tumors to predict treatment responses and to customize therapies accordingly. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. Therefore, the demand for personalized medicine is a key factor propelling the growth of the patient-derived xenograft (PDX) models market.

Which Segments Are Gaining Traction In The Patient Derived Xenograft (PDX) Models Market?

The patient derived xenograft (pdx) models market covered in this report is segmented –

1) By Type: Mice Models, Rat Models

2) By Technique: Heterotopic Implantation, Orthotropic Implantation

3) By Tumor Type: Gastrointestinal Tumor Models, Lung Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Other Tumor Models

4) By Application: Preclinical Drug Development, Precision Medicine, Co-Clinical Trials, Basic Cancer Research

5) By End-User: Academic And Research Organizations, Contract Research Organizations, Pharmaceutical And Biotechnological Companies, Other End-Users

Subsegments:

1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice), Humanized Mice Models, Genetically Modified Mice Models

2) By Rat Models: Immunodeficient Rat Models, Humanized Rat Models, Genetically Modified Rat Models

Which Trends Are Expected To Influence The Patient Derived Xenograft (PDX) Models Market In The Upcoming Years?

Leading companies in the patient-derived xenograft (PDX) models market are developing advanced models equipped with in vivo bioluminescence imaging capabilities for continuous monitoring of tumor growth. In vivo bioluminescence imaging supports PDX models by allowing noninvasive, real-time observation of tumor metastasis and treatment responses, thereby boosting the effectiveness of preclinical research in drug development. For instance, in March 2024, InVitro Research Solutions Private Limited, an India-based Contract Research Organization (CRO), launched a novel orthotopic model of human glioblastoma in NSG-SGM3 mice, utilizing patient-derived xenografts (PDX) and in vivo bioluminescence imaging. This model aims to facilitate personalized treatment for glioblastoma, which is the most common and aggressive type of brain cancer. Such models are essential for understanding glioblastoma biology and evaluating new targeted therapies and immunotherapies to achieve better patient outcomes.

Who Are The Major Companies Operating In The Patient Derived Xenograft (PDX) Models Market?

Major companies operating in the patient derived xenograft (pdx) models market are WuXi AppTec Co Ltd, Charles River Laboratories International Inc, The Jackson Laboratory, Inotiv Inc, Taconic Biosciences Inc, Crown Bioscience Inc, Champions Oncology Inc, Certis Oncology Solutions Inc, EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH, InnoSer, Envigo, Oncodesign Services SA, Horizon Discovery Ltd, Pharmatest Services Ltd, Hera BioLabs, Xenopat, Noble Life Sciences, Medicilon, TheraIndx Life Sciences, Invivocue, InVitro Research Solutions Private Limited, NexusPharma, Mediford Corporation, GemPharmatech Co Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/patient-derived-xenograft-pdx-models-global-market-report

Which Regions Are Poised For Strategic Growth In The Patient Derived Xenograft (PDX) Models Market?

North America was the largest region in the patient derived xenograft (PDX) models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (pdx) models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Patient Derived Xenograft (PDX) Models Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17226&type=smp

Browse Through More Reports Similar to the Global Patient Derived Xenograft (PDX) Models Market 2026, By The Business Research Company

Patient Simulators Market Report 2026

https://www.thebusinessresearchcompany.com/report/patient-simulators-global-market-report

Xenotransplantation Market Report 2026

https://www.thebusinessresearchcompany.com/report/xenotransplantation-global-market-report

Xerostomia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795